Dr.Liu isa clinical pharmacistin theDepartment of Pharmacy. She obtained her PhD in Pharmacology at Institute of Clinical Pharmacology in Sun Yat-sen University. she has rich experience in the whole process of pharmaceutical care for patients with lymphoma, and even complex drug combination management and adverse reaction identification. Her major research interests focus on therapeutic drug monitoring for targeted anti-tumor drug, pharmacokinetics , pharmacogenomics and personalized use of anti tumor drugs.  Dr.Liu has undertaken different research grants including the Youth Program of National Natural Science Foundation of China. She has published more than 10 SCI papers as first author or corresponding author.

Therapeutic drug monitoring for targeted anti-tumor drug, pharmacokinetics, pharmacogenomics and personalized use of anti tumor drugs

 PhD in Pharmacology,Sun Yat-sen University

1.Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. Liu S, Huang H, Chen R, Wang Z, Guan Y, et al. Acta Pharmacol Sin. 2021 Apr;42(4):641-647. doi: 10.1038/s41401-020-0479-2.

2.Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes Correlates With Clinical Outcome. Liu S, Wang Z, Chen R, Wang X, Fang X, et al. Front Pharmacol. 2022 Jan 2613:788824. doi: 10.3389/fphar.2022.788824.

3.Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. Liu S, Wang Z, Chen R, Huang H, Wang X, et al. Clin Transl Sci. 2022 Mar15(3):680-690. doi:10.1111/cts.13186.PMC8932720.

4.Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Li J, Liu S, Fu Q, Zhang Y, Wang X, et al. Pharmacogenomics. 2015;16(12):1355-65. doi: 10.2217/pgs.15.78.

Updated by International Office, Sun Yat-sen University Cancer Center